Comparison of Immunological and Virological Recovery with Rapid, Early, and Late Start of Antiretroviral Treatment in Naive Plwh: Real-World Data

References

• Yoshimura K. Current status of HIV/AIDS in the ART era. J Infect Chemother. 2017;23(1):12–16. doi:10.1016/j.jiac.2016.10.002
   PubMed Web of Science ®Google Scholar
• Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV, according to the timing of diagnosis. AIDS. 2012;26(3):335–343. doi:10.1097/QAD.0b013e32834dcec9
   PubMed Web of Science ®Google Scholar
• Walker BD, Hirsch MS. Antiretroviral therapy in early HIV infection. N Engl J Med. 2013;368(3):279–281. doi:10.1056/NEJMe1213734
   PubMed Web of Science ®Google Scholar
• Panel on antiretroviral guidelines for adults and adolescents; 2017. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed May 16, 2023.
   Google Scholar
• World Health Organization. 2016, Diagnosis, treatment and care for key populations; 2016. Available from: http://apps.who.int/iris/bitstream/10665/246200/1/9789241511124-eng.pdf?ua=13. Accessed May 16, 2023.
   Google Scholar
• EACS guidelines, version 9.0; 2017. Available from: http://www.eacsociety.org/guidelines/eacsguidelines/eacs-guidelines.html. Accessed May 16, 2023.
   Google Scholar
• Lundgren JD, Babiker AG, Gordin F, et al.; Insight Start Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
   PubMed Web of Science ®Google Scholar
• Danel C, Moh R; Tempranoanrs Study Group. Atrial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–822.
   PubMed Web of Science ®Google Scholar
• Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS. 2018;32(1):17–23. doi:10.1097/QAD.0000000000001671
   PubMed Web of Science ®Google Scholar
• Rosen S, Maskew M, Fox MP, et al. Affiliations expand initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13(5):e1002015. doi:10.1371/journal.pmed.1002015
   PubMed Web of Science ®Google Scholar
• Amanyir G, Semitala FC, Namusobya J, et al. Effects of a multicomponent intervention to streamline the initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomized trial. Lancet HIV. 2016;3(11):539–548. doi:10.1016/S2352-3018(16)30090-X
   Web of Science ®Google Scholar
• Koenig SP, Dorvil N, Dévieux JG, et al. Same-day HIV testing with the initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial. PLOS Med. 2017;14(7):e100235. doi:10.1371/journal.pmed.1002357
   Web of Science ®Google Scholar
• Labhardt ND, Ringera I, Lejone TI, et al. Effect of offering same-day ART vs. usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE randomized clinical trial. JAMA. 2018;319(11):1103–1112. doi:10.1001/jama.2018.1818
   PubMed Web of Science ®Google Scholar
• Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy; 2017. Geneva, Switzerland. Available from: https://apps.who.int/iris/bitstream/handle/10665/255884/9789241550062-eng.pdf?sequence=1. Accessed December 24, 2021.
   Google Scholar
• Halperin J, Butler I, Conner K, et al. Linkage, and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans. AIDS Patient Care STDS. 2018;32(2):39–41. doi:10.1089/apc.2017.0309
   PubMed Web of Science ®Google Scholar
• Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting. J Acquir Immune Defic Syndr. 2017;74(1):44–45. doi:10.1097/QAI.0000000000001134
   PubMed Web of Science ®Google Scholar
• Olsen HA, Sarkodie E, Coleman M, et al. Fast forward to viral suppression: immediate initiation of ARVs following Reactive HIV+ test result or engagement in HIV Care for the first time at a community health center in Washington. In IAPAC Miami, DC; 2018.
   Google Scholar
• Colasanti J, Sumitani J, Mehta CC, et al. Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the Southern United States. Open Forum Infect Dis. 2018;5(6):ofy104. doi:10.1093/ofid/ofy104
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Guideline for use antiretroviral agents in adults and adolescents with HIV; 2019. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Accessed May 16, 2023.
   Google Scholar
• Saag M, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society–USA panel. JAMA. 2018;320(4):379–396. doi:10.1001/jama.2018.8431
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society (EACS) Guidelines. Version 10.1; 2020. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.htlm. Accessed December, 2021.
   Google Scholar
• General Directorate of Public Health. Statistical data of communicable diseases department: HIV/AIDS. Ankara: T.C. Ministry of Health. Available from: http://www.thsk.gov.tr/component/k2/353-istatiksel-veriler/bulasici-hastaliklar-dairebaskanligi-istatiksel-veriler.html. Accessed May 16, 2023.
   Google Scholar
• Erdinc FS, Dokuzoguz B, Unal S, et al. Temporal trends in the epidemiology of HIV in Turkey. Curr HIV Res. 2020;18(4):258–266. doi:10.2174/1570162X18666200427223823
   PubMed Web of Science ®Google Scholar
• Turkish Ministry of Health. Turkey HIV/AIDS control program, Türkiye HIV/AIDS control programı; 2019. https://hsgm.saglik.gov.tr/depo/birimler/Bulasici-hastaliklardb/hastaliklar/HIV-ADS/Tani-Tedavi_Rehberi/HIV_AIDS_Kontrol_Programi.pdf. Accessed January, 2022.
   Google Scholar
• Hosmer DW, Lemeshow S. Model-Building Strategies and Methods for Logistic Regression. in Applied Logistic Regression 91–142. Hoboken: John Wiley & Sons, Inc.; 2005. doi:10.1002/0471722146.ch4
   Google Scholar
• World Health Organization. Guideline on when to start antiretroviral therapy and on preexposure prophylaxis for HIV; 2015. www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/. Accessed January, 2022.
   Google Scholar
• Medland NA, Chow EPF, McMahon JH, et al. Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: dramatic fall from 2011 to 2015. PLoS One. 2017;12(5):e0177634.
   PubMed Web of Science ®Google Scholar
• Le Guillou A, Pugliese P, Raffi F. Reaching the Second and Third Joint United Nations Programme on HIV/AIDS 90–90-90 targets is accompanied by a dramatic reduction in primary human immunodeficiency virus (HIV) infection and recent HIV infections in a large French nationwide HIV cohort. Clin Infect Dis. 2020;71(2):293–300. doi:10.1093/cid/ciz800
   PubMed Web of Science ®Google Scholar
• Whitlock G, Carbonell M, Blackwell S, et al. G. Rapid initiation of antiretroviral therapy in those with newly diagnosed HIV infection in London. UK HIV Med. 2019;20(10):699–703. doi:10.1111/hiv.12780
   PubMed Web of Science ®Google Scholar
• Huang YC, Sun HY, Chuang YC, et al. Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: real-world experience from a single-center retrospective cohort in Taiwan. BMJ Ope. 2019;9(9):e033246. doi:10.1136/bmjopen-2019-033246
   PubMed Web of Science ®Google Scholar
• Scheer S, Hsu L, Schwarcz S, et al. Trends in the san francisco human immunodeficiency virus epidemic in the “Getting to Zero” Era. Clin Infect Dis. 2018;66(7):1027–1034. doi:10.1093/cid/cix940
   PubMed Web of Science ®Google Scholar
• Coffeya S, Bacchettib P, Sachdevc D, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. AIDS. 2019;33(5):825–832. doi:10.1097/QAD.0000000000002124
   PubMed Web of Science ®Google Scholar
• Halperin J, Conner K, Butler I, et al. A care continuum of immediate ART for newly diagnosed patients and patients presenting later to care at a federally qualified health center in New Orleans. Open Forum Infect Dis. 2019;6(4):ofz161. doi:10.1093/ofid/ofz161
   PubMed Web of Science ®Google Scholar
• Raymond A, Hill A, Pozniak A. Large disparities in HIV treatment cascades between eight European and high-income countries - analysis of breakpoints. J Int AIDS Soc. 2014;17(3):19507. doi:10.7448/IAS.17.4.19507
   PubMedGoogle Scholar
• Levi J, Pozniak A, Heath K, Hill A. The impact of HIV prevalence, conflict, corruption, and GDP/capita on treatment cascades: data from 137 countries. J Virus Erad. 2018;4(2):80–90. doi:10.1016/S2055-6640(20)30249-1
   PubMed Web of Science ®Google Scholar
• Drew RS, Rice B, Rüütel K, et al. HIV continuum of care in Europe and Central Asia. HIV Med. 2017;18(7):490–499. doi:10.1111/hiv.12480
   PubMed Web of Science ®Google Scholar
• Le Moing V, Thiébaut R, Chêne G, et al.; APROCO Study Group SO. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2002;185(4):471. doi:10.1086/338929
   PubMed Web of Science ®Google Scholar
• Sarigul F, User U, Oztoprak N. Comparison of ımmunologıcal and virological recovery of raltegravır, elvitegravir and dolutegravir ın HIV-1 ınfected naive patients. Acta Medica Mediterranea. 2019;35:3077.
   Web of Science ®Google Scholar
• Hileman C, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep. 2017;14(3):93–100. doi:10.1007/s11904-017-0356-x
   PubMed Web of Science ®Google Scholar
• Mussini C, Lorenzini P, Cozzi-Lepri A, et al.; Icona Foundation Study Group. CD4/CD8 ratio normalization and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015;3(2):98–106. doi:10.1016/S2352-3018(15)00006-5
   Google Scholar
• Torti C, Prosperi M, Motta D, et al. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV infected patients on long-term suppressive antiretroviral therapy. Clin Microbiol Infect. 2012;18(5):449–458. doi:10.1111/j.1469-0691.2011.03650.x
   PubMed Web of Science ®Google Scholar
• Thornhill J, Inshaw J, Kaleebu P, et al. Enhanced Normalization of CD4/CD8 ratio with earlier antiretroviral therapy at primary HIV infection. J Acquir Immune Defic Syndr. 2016;73(1):69–73. doi:10.1097/QAI.0000000000001013
   PubMed Web of Science ®Google Scholar
• Davy-Mendez T, Napravnik S, Zakharova O, et al. Acute HIV Infection and CD4/CD8 ratio normalization after antiretroviral therapy initiation. J Acquir Immune Defic Syndr. 2018;79(4):510–518. doi:10.1097/QAI.0000000000001843
   PubMed Web of Science ®Google Scholar
• Cao W, Mehraj V, Trottier B, et al. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8 T-cell counts. Clin Infect Dis. 2016;62(2):250–257. doi:10.1093/cid/civ809
   PubMed Web of Science ®Google Scholar
• Trickey A, May MT, Schommers P, et al. CD4:CD8 Ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: the antiretroviral therapy cohort collaboration (ART-CC). Clin Infect Dis. 2017;65(6):959–966. doi:10.1093/cid/cix466
   PubMed Web of Science ®Google Scholar
• Veil R, Poizot-Martin I, Reynes J, et al. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection. AIDS. 2020;34(4):493–500. doi:10.1097/QAD.0000000000002447
   PubMed Web of Science ®Google Scholar
• Deeks ED, Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: a Review in HIV-1 Infection. Drugs. 2018;78(17):1817–1828. doi:10.1007/s40265-018-1010-7
   PubMed Web of Science ®Google Scholar
• Zuppelli A, Mancenid M, Scutaru J, et al.; Gilead Sciences, Foster City, CA. Real world community-based HIV rapid start antiretroviral with BFTAF versus conventional HIV antiretroviral therapy start - The RoCHaCHa Study, a pilot study IDWeek 2020 Oct 21–25 virtual reported by Jules Levin; 2020.
   Google Scholar
• Cuzin L, Cotte L, Delpierre C, et al. Dat’AIDS Study group Too fast to stay on track? Shorter time to the first anti-retroviral regimen is not associated with better retention in care in the French Dat’AIDS cohort. PLoS One. 2019;14(9):e022206. doi:10.1371/journal.pone.0222067
   Web of Science ®Google Scholar
• Zhao Y, Wu Z, McGoogan JM, et al. Nationwide cohort study of antiretroviral therapy timing: treatment dropout and virological failure in China, 2011–2015. Clin Infect Dis. 2019;68(1):43–50. doi:10.1093/cid/ciy400
   PubMed Web of Science ®Google Scholar